TY - JOUR

T1 - Mannose-binding lectin and risk of infections in type 2 diabetes

T2 - A Danish cohort study

AU - Gedebjerg, Anne

AU - Thomsen, Reimar Wernich

AU - Kjaergaard, Alisa Devedzic

AU - Steffensen, Rudi

AU - Nielsen, Jens Steen

AU - Rungby, Jørgen

AU - Friborg, Søren Gunnar

AU - Brandslund, Ivan

AU - Thiel, Steffen

AU - Beck-Nielsen, Henning

AU - Sørensen, Henrik Toft

AU - Hansen, Troels Krarup

AU - Bjerre, Mette

N1 - Publisher Copyright: © 2021 Elsevier Inc.

PY - 2021

Y1 - 2021

N2 - Aims: In individuals at increased risk of infections, e.g., patients with type 2 diabetes, low MBL may have detrimental effects. We used the Mendelian randomization principle to examine whether genetically low MBL is a risk factor for developing infections in patients with type 2 diabetes. Methods: Serum MBL (n = 7305) and MBL genotype (n = 3043) were determined in a nationwide cohort of patients with new type 2 diabetes and up to 8 years follow-up for hospital-treated infections and community-based antimicrobial prescriptions. The associations were examined in spline and Cox regression analyses. Results: 1140 patients (16%) were hospitalized with an infection and 5077 patients (70%) redeemed an antimicrobial prescription. For low (≤100 μg/L) versus intermediate (101–1000 μg/L) serum MBL concentration, the adjusted hazard ratios (aHRs) were 1.13(95% confidence interval, 0.96–1.33) for any hospital-treated infections and 1.19(1.01–1.41) for bacterial infections. Low MBL expression genotype was not associated with risk of any hospital-treated infections except for diarrheal diseases (aHR 2.23[1.04–4.80]). Low MBL expression genotype, but not low serum MBL, was associated with increased risk for antimicrobial prescriptions (aHR 1.18[1.04–2.34] and antibacterial prescriptions 1.20[1.05–1.36]). Conclusions: Low MBL is a weak causal risk factor for developing infections in patients with type 2 diabetes.

AB - Aims: In individuals at increased risk of infections, e.g., patients with type 2 diabetes, low MBL may have detrimental effects. We used the Mendelian randomization principle to examine whether genetically low MBL is a risk factor for developing infections in patients with type 2 diabetes. Methods: Serum MBL (n = 7305) and MBL genotype (n = 3043) were determined in a nationwide cohort of patients with new type 2 diabetes and up to 8 years follow-up for hospital-treated infections and community-based antimicrobial prescriptions. The associations were examined in spline and Cox regression analyses. Results: 1140 patients (16%) were hospitalized with an infection and 5077 patients (70%) redeemed an antimicrobial prescription. For low (≤100 μg/L) versus intermediate (101–1000 μg/L) serum MBL concentration, the adjusted hazard ratios (aHRs) were 1.13(95% confidence interval, 0.96–1.33) for any hospital-treated infections and 1.19(1.01–1.41) for bacterial infections. Low MBL expression genotype was not associated with risk of any hospital-treated infections except for diarrheal diseases (aHR 2.23[1.04–4.80]). Low MBL expression genotype, but not low serum MBL, was associated with increased risk for antimicrobial prescriptions (aHR 1.18[1.04–2.34] and antibacterial prescriptions 1.20[1.05–1.36]). Conclusions: Low MBL is a weak causal risk factor for developing infections in patients with type 2 diabetes.

KW - Association

KW - Cohort study

KW - Epidemiology

KW - Infection

KW - Mannose-binding lectin

KW - Type 2 diabetes

U2 - 10.1016/j.jdiacomp.2021.107873

DO - 10.1016/j.jdiacomp.2021.107873

M3 - Journal article

C2 - 33627253

AN - SCOPUS:85101138809

VL - 35

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

IS - 5

M1 - 107873

ER -